Advertisement

 

 

Experimental data of co-crystals of Etravirine and L-tartaric acid.

Experimental data of co-crystals of Etravirine and L-tartaric acid.
Author Information (click to view)

Rekdal M, Pai A, Bs M,


Rekdal M, Pai A, Bs M, (click to view)

Rekdal M, Pai A, Bs M,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Data in brief 2017 11 0716() 135-140 doi 10.1016/j.dib.2017.11.019

Abstract

Etravirine is a drug used alongside other medication in the treatment of HIV and is a non-nucleoside reverse transcriptase inhibitor. It is a BCS class IV drug, having low solubility and high permeability (Drugbank, https://www.drugbank.ca/drugs/DB06414) [1]. As a result, large doses of the drug are required for treatment. Two pills have to be taken twice a day, making it a "pill burden" (Intelence, http://www.intelence.com/hcp/dosing/administration-options) [2]. Therefore, attempts of co-crystallizing Etravirine are attractive as the solubility of the drug tends to increase in this solid form (Schultheiss and Newman, 2009) [3]. In this study Etravirine co-crystals were synthesized in the molar ratios 1:1, 1:2 and 2:1 with L-tartaric acid as the co-former. Both slow evaporation and physical mixture was performed to mix the components. DSC values of final products are presented as well as FTIR spectra to observe the altered intermolecular interactions. A chemical stability test was performed after seven days using area under curve data from an HPLC instrument.

Submit a Comment

Your email address will not be published. Required fields are marked *

4 × four =

[ HIDE/SHOW ]